Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk Q3 in line with expectations, narrows FY guidance range
Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.
Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drug Sales.
Investors want assurance the new GLP-1 weight-loss medicines can live up to their blockbuster expectations.
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk AS NVO will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours.
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
Novo Nordisk (NVO), maker of popular weight-loss drugs Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall Street analysts generally bullish on the Danish drugmaker's stock.
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Wegovy effective in MASH fatty liver fibrosis trial says Novo
Novo Nordisk (NYSE:NVO) has reported another successful trial for its Wegovy or Semaglutide drug, this time in the treatment of fibrosis caused by the fatty liver condition known as MASH. Headline results from part 1 of the ongoing ESSENCE trial, a phase three, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis, showed it met its primary endpoint, Compared to placebo there was a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, said the Danish group which is Europe's largest company.
Novo's Wegovy helps improve liver fibrosis in late-stage trial
Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
US FDA says lowest dose of Novo Nordisk's weight-loss drug now available
The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website showed on Wednesday.
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which is marketed by Novo Nordisk (NYSE:NVO) under the brand names Ozempic and Wegovy. The study demonstrated that this combination effectively promotes liver homeostasis and reduces inflammation in preclinical models of diet-induced obesity.
